Technology -
Hardware, Equipment & Parts - NASDAQ - CN
$ 1.37
-7.43 %
$ 2.75 M
Market Cap
-0.2
P/E
1. INTRINSIC VALUE
Balance Sheet
Ostin Technology Group Co., Ltd.
| Current Assets | 20.8 M |
| Cash & Short-Term Investments | 1.02 M |
| Receivables | 5.96 M |
| Other Current Assets | 13.9 M |
| Non-Current Assets | 30.2 M |
| Long-Term Investments | 0 |
| PP&E | 24.5 M |
| Other Non-Current Assets | 5.71 M |
| Current Liabilities | 41 M |
| Accounts Payable | 6.34 M |
| Short-Term Debt | 26.2 M |
| Other Current Liabilities | 8.45 M |
| Non-Current Liabilities | 2.23 M |
| Long-Term Debt | 1.71 M |
| Other Non-Current Liabilities | 517 K |
EFFICIENCY
Earnings Waterfall
Ostin Technology Group Co., Ltd.
| Revenue | 32.5 M |
| Cost Of Revenue | 30.8 M |
| Gross Profit | 1.69 M |
| Operating Expenses | 11.2 M |
| Operating Income | -9.53 M |
| Other Expenses | 660 K |
| Net Income | -10.2 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ostin Technology Group Co., Ltd.
| Net Income | -10.2 M |
| Depreciation & Amortization | 4.78 M |
| Capital Expenditures | -2.44 M |
| Stock-Based Compensation | 0 |
| Change in Working Capital | -302 K |
| Others | -258 K |
| Free Cash Flow | -7.38 M |
Wall Street Analysts Price Targets
Ostin Technology Group Co., Ltd.
OST has no price targets from Wall Street.
4. DIVIDEND
ANALYSIS
OST does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Ostin Technology Group Co., Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that it has submitted a request for a formal meeting with the Center for Biologics Evaluation and Research (CBER) of the United States Food & Drug Administration (FDA) to gain alignment on the clinical endpoints required to support Breakthrough Therapy Designation (BTD) and Accelerated Approval v.
businesswire.com
- 1 week ago
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria monocytogenes (Lm) immunotherapeutic cancer biologic drug candidate in the prevention or delay of fully-resected, recurrent, lung metastatic osteosarcoma. “We are making rapid progress in putting together an appropriate data package to achieve accelerated.
businesswire.com
- 2 weeks ago
OS Therapies' OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers
NEW YORK--(BUSINESS WIRE)--OS Therapies (NYSE-A: OSTX) (“OS Therapies” or “the Company”), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today announced that OST-HER2 is featured in the upcoming movie Shelter Me: The Cancer Pioneers. The movie offers a look into canine comparative oncology, a field that compares treatment of cancers in dogs to those in people, and covers developing treatments for rare forms of cancer. OST-HER2 is an immunotherapy for.
businesswire.com
- 3 weeks ago
OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has been awarded a presentation slot at the MIB Agents Factor Osteosarcoma Conference to be held June 26-28, 2025 in Salt Lake City, Utah. Key data will be presented from the Company's Phase 2b clinical trial of OST-HER2 in the prevention of recurrent, fully resected, lung metastatic osteosarcoma.
businesswire.com
- 1 month ago
OS Therapies Schedules United Kingdom's Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has scheduled a Scientific Advice Meeting (SAM) in the third quarter of 2025 to discuss the Innovative Licensing and Access Pathway (ILAP) with the United Kingdom's (UK) Medicines and Healthcare products Regulatory Agency (MHRA) for OST-HER2, its immunotherapy candidate for the prevention of recu.
businesswire.com
- 1 month ago
OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it received a Notice of Allowance from the United States Patent & Trademark Office (USPTO) that a patent will be issued covering the manufacturing methods required for the OST-HER2 commercial product. The USPTO granted a Patent Term Adjustment of 572 days, providing market exclusivity for the OS.
businesswire.com
- 1 month ago
OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced that it has entered into agreements for the commercial manufacture of OST-HER2. The Company is currently organizing additional data in relation to the recently-completed treatment phase of its Phase 2b trial of OST-HER2 in the prevention of recurrence of lung metastatic osteosarcoma in preparation for a.
businesswire.com
- 2 months ago
Why Is Pediatric-Cancer Focused OS Therapies Stock Trading Higher On Wednesday?
On Wednesday, OS Therapies, Inc. OSTX revealed data from a Phase 2b trial of OST-HER2 (OST31-164), a HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma, a rare, cancerous bone tumor that develops in bone-forming cells.
benzinga.com
- 3 months ago
OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma
NEW YORK--(BUSINESS WIRE)--OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, today announced positive data from a Phase 2b clinical trial (NCT04974008) of OST-HER2 (OST31-164) - the Company's HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma. The data demonstrate statistically significant res.
businesswire.com
- 3 months ago
Ostin Technology Group Announces Update to Effective Date of Reverse Share Split
Nanjing, China, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced an update to the effective date of its previously approved reverse share split of the Company's Class A ordinary shares, with the split ratio set at 1-for-10 (the “Reverse Share Split”). The Reverse Share Split was approved by the Company's shareholders at an extraordinary general meeting held on November 25, 2024. The effective date for the Reverse Share Split has been revised from December 26, 2024 to December 31, 2024 and the Company's Class A ordinary shares will begin trading on an adjusted basis, reflecting the Reverse Share Split, on December 31, 2024, under the existing ticker symbol “OST.” The new CUSIP number for the Company's Class A ordinary shares will be G67927114.
globenewswire.com
- 3 months ago
Ostin Technology Group Announces Effective Date of Reverse Share Split
Nanjing, China, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, today announced that it has resolved to effect a reverse share split of the Company's ordinary shares, with the split ratio set at 1-for-10 (the “The Reverse Share Split”). The Reverse Share Split was approved by the Company's shareholders at an extraordinary general meeting held on November 25, 2024. The Company's Class A ordinary shares will begin trading on an adjusted basis, reflecting the Reverse Share Split, on December 26, 2024, under the existing ticker symbol “OST.” The new CUSIP number for the Company's Class A ordinary shares will be G67927114.
globenewswire.com
- 4 months ago
Ostin Technology Group Announces Results of Extraordinary General Meeting
Nanjing, China, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Ostin Technology Group Co., Ltd. ("the Company") (Nasdaq: OST), a leading supplier of display modules and polarizers based in China, announced the results of an Extraordinary General Meeting held on November 26, 2024, at 10:00 a.m. Beiijng Time (November 25, 2024, at 9:00 p.m., U.S. Eastern time) at its executive office at Floor 1, Building F4, 1 Zidong Road, Qixia District, Nanjing, Jiangsu Province, China.
globenewswire.com
- 4 months ago
8. Profile
Summary
Ostin Technology Group Co., Ltd. OST
COUNTRY
CN
INDUSTRY
Hardware, Equipment & Parts
MARKET CAP
$ 2.75 M
Dividend Yield
0.00%
Description
Ostin Technology Group Co., Ltd. designs, develops, and manufactures thin-film transistor liquid crystal display (TFT-LCD) modules and polarizers in China. The company offers TFT-LCD solutions for drive IC, TCON board, and power supply applications; back light systems and special modules; LC display modules, touch panel modules, and smart display terminals; and polarizers used in the TFT-LCD display modules. It offers display modules to markets, such as consumer electronics, including AIOs, monitors, laptop computers, and tablets; automotive displays, including dashboard, and navigation and multimedia systems; and outdoor LCD displays, which are used to display multimedia graphics, such as company advertisements, promotions, scoreboards, and traffic signs. The company sells its products directly to customers, as well as to customers' designated system integrators. Ostin Technology Group Co., Ltd. was founded in 2010 and is based in Nanjing, China with manufacturing facilities in China.
Contact
Building 2, 101/201, Nanjing, 210046
https://www.austinelec.com
IPO
Date
April 27, 2022
Employees
117
Officers
Mr. Kui Sen Lai
Co-Chief Executive Officer & Director
Mr. Tao Ling
Co-Chief Executive Officer & Chairman
Mr. Xiaohong Yin
Company Secretary & Director
Ms. Qiaoyun Xie
Chief Financial Officer
Mr. Xiaodong Zhai
Chief Technology Officer